13F filer · CIK 1856083
Deep Track Capital, LP
GREENWICH, CT · filing since Q4 2021 · last filing Aug 14, 2026
Reported value
$6.9B
+$746.9M vs prior
Positions
67
New / sold out
19 / 15
Added / reduced
22 / 15
Turnover
27.7%
buys $1.8B · sells $2.3B
Top-10 weight
39.6%
Biggest buys vs Q1 2026
| Change | Security | Shares change | Change % | Est. trade value |
|---|---|---|---|---|
| New | ALNYLAM PHARMACEUTICALS INC | +825,000 | – | +$248.3M |
| Added | VERADERMICS INC | +1,500,000 | +300.0% | +$184.4M |
| New | HEMAB THERAPEUTICS HLDGS INC | +3,602,093 | – | +$132.3M |
| Added | BIOMARIN PHARMACEUTICAL INC | +2,157,481 | +187.6% | +$123.5M |
| New | GH RESEARCH PLC | +3,333,334 | – | +$89.6M |
| New | GENMAB A/SCALL | +3,000,000 | – | +$82.4M |
| New | UNITED THERAPEUTICS CORP DEL | +123,616 | – | +$67.0M |
| New | AVALO THERAPEUTICS INC | +3,610,000 | – | +$66.7M |
| Added | CELLDEX THERAPEUTICS INC NEW | +1,655,172 | +128.9% | +$61.6M |
| New | ALTIMMUNE INC | +19,250,000 | – | +$58.5M |
31 more rows. Subscribe for $29/month to see every row, download the data and use the API.
Biggest sells vs Q1 2026
| Change | Security | Shares change | Change % | Est. trade value |
|---|---|---|---|---|
| Sold out | SPDR SERIES TRUSTPUT | -10,000,000 | -100.0% | $-1.3B |
| Sold out | APELLIS PHARMACEUTICALS INC | -4,532,374 | -100.0% | $-182.3M |
| Sold out | CENTESSA PHARMACEUTICALS PLC | -3,158,041 | -100.0% | $-125.4M |
| Reduced | AXSOME THERAPEUTICS INC. | -400,000 | -36.4% | $-97.9M |
| Reduced | IMMUNOVANT INC | -2,185,820 | -19.0% | $-84.2M |
| Sold out | BRIDGEBIO PHARMA INC | -841,445 | -100.0% | $-62.5M |
| Reduced | CYTOKINETICS INC | -674,320 | -49.1% | $-57.4M |
| Sold out | TERNS PHARMACEUTICALS INC | -1,073,877 | -100.0% | $-56.6M |
| Reduced | MBX BIOSCIENCES INC | -1,025,000 | -37.2% | $-56.6M |
| Reduced | IMMUNOCORE HLDGS PLC | -1,620,666 | -83.9% | $-51.5M |
20 more rows. Subscribe for $29/month to see every row, download the data and use the API.
Estimated trade value = change in shares × this quarter's implied price. 13F filings show quarter-end positions, not individual trades.
Reported value by quarter
Holdings · Q2 2026
| # | Security | Shares | Value | Weight |
|---|---|---|---|---|
| 1 | GUARDANT HEALTH INCCOM | 3,393,312 | $509.1M | 7.41% |
| 2 | IMMUNOVANT INCCOM | 9,341,151 | $359.9M | 5.24% |
| 3 | STRUCTURE THERAPEUTICS INCSPONSORED ADS | 4,740,072 | $254.4M | 3.70% |
| 4 | VAXCYTE INCCOM | 4,300,000 | $250.0M | 3.64% |
| 5 | ALNYLAM PHARMACEUTICALS INCCOM | 825,000 | $248.3M | 3.61% |
| 6 | VERADERMICS INCCOMMON STOCK | 2,000,000 | $245.9M | 3.58% |
| 7 | TARSUS PHARMACEUTICALS INCCOM | 3,666,768 | $230.8M | 3.36% |
| 8 | NUVALENT INCCOM | 1,783,322 | $220.2M | 3.21% |
| 9 | ALKERMES PLCSHS | 4,000,000 | $209.6M | 3.05% |
| 10 | OCULAR THERAPEUTIX INCCOM | 19,686,282 | $193.3M | 2.81% |
57 more rows. Subscribe for $29/month to see every row, download the data and use the API.